Tenofovir Disoproxil Fumarate, an acyclic nucleotide analogue of adenosine monophosphate, is a pro-drug of Tenofovir. It shows activity against hepatitis B virus polymerase and HIV reverse transcriptase after phosphorylation to the active diphosphate form. Tenofovir diphosphate inhibits viral polymerase (reverse transcriptase) by directly competing with the natural substrate deoxyribonucleotide and by causing DNA chain termination after its incorporation into viral DNA.
Tenofovir Disoproxil Fumarate
(in Tablet form)
The recommended dose of Tenofovir in chronic hepatitis B virus infection in adults 18 years of age and older with adequate renal function is 300 mg once daily with or without food.
Renal Impairment: Haemodialysis patients: 300 mg once every 7 days or after a cumulative total of 12 hr of dialysis.
CrCl (10-29 mL/min): 300 mg 72-96 hrly.
CrCl (30-49 mL/min): 300 mg 48 hrly.
Dose adjustment in hepatic impairment: No dose adjustment is required in patients with hepatic impairment.
Manufacturer: Square Pharmaceutical Ltd.